Newsletter Subject

When this indicator lights up, you better listen 📈👂

From

bullseyeoptiontrading.com

Email Address

bullseye@b.bullseyeoptiontrading.com

Sent On

Wed, Oct 11, 2023 01:11 PM

Email Preheader Text

Becoming my favorite setup ?

Becoming my favorite setup                                                                                                                                                                                                                                                                                                                                                                                                                 October 11, 2023  [Hot Stock]( I [Surprise]( 🎁 *Sponsored by Sica Media As we start today, I continue to have bonds in focus. I know, this is boring “old guy” stuff, but if you learn to read the quiet whisperings of the stock market’s tea leaves, you will become a much better trader. And right now, bonds are driving the ship… so we better pay attention! This morning, TLT is breaking above the key $87 level I have been banging the table on for weeks now (make sure you are paying attention to that). I think this is going to keep a bid under stocks, we will likely see the market dips bought, and we think the rally will move even higher from here. This is a “green light” time in the market for my personal trading. If you are like me, you are scouring the market for new ideas right now. Well, I don’t see many setups better than what I am seeing with NLS Pharmaceuticals (NLSP) right now. I know it is a small stock that is trading under a buck – but that is exactly what I am drawn to. Those are the types of stocks that can make incredible percentage gain moves in a very short period of time. Just this morning in pre-market we already saw NLSP make a 12% move, and that is on top of the nearly 10% gain it posted yesterday. Let me get out my calculator really quick 🧮… From my basic math, that looks like a 20%+ move for NLSP within a day. Congrats to everyone who paid attention to this yesterday morning when I brought it to your attention. You have been rewarded with a delicious stock move, all for simply opening an email. What a world we live in. Now, the question on everyone’s mind is where are things headed from here? Well, no one ever knows for sure, but what I do know is that I am seeing one of the strongest indicators in the entire market right now. See this cluster of “GO” signals? When I look at 1000’s of charts, in any timeframe, this is what I typically see before a major trend reversal. And if history holds up, NLSP has had a history of making big, double-digit moves when it decides to reverse course. I would certainly rather be early in a move like that rather than waiting on the sidelines and watching it happen without me. If you haven’t taken a look at NLSP yet, I’d strongly encourage you to pull it up on your screen and see what you think. Yesterday, I gave the following baseball analogy about what I look for when it comes to a great trade setup. A “great trade setup” is when I see an opportunity so obvious, it is stupid not to take a swing. It may not work all of the time, but it is always worth a swing from me. I wait for what I call “fat pitches” to come along — high-confidence moves based on solid technicals. Well, folks, that is exactly what I saw coming over the plate yesterday, and it is building today. When you see a nice, slow, fat pitch coming your way… all you need to do is get a plan and take a swing. Let me explain… I first wrote to you about Swiss-based NLS Pharmaceutics (NASDAQ: NLSP) in late-August. As I wrote at the time, “We don’t often see setups like these so it is imperative to take full advantage when they do come around.” If you paid attention to that, you then witnessed NLSP make a double-digit move higher over the next week, before consolidating one more time, and ultimately making a clear breakout over 20% higher, much like we just saw in the last 24-hours. Well folks, this is the reason I’ve stayed tuned to the NLSP story since then and right now my favorite indicators are signaling that we may be on the cusp of another major breakout. Revisit this chart I shared with you yesterday before the market opened: That’s the analysis of an advanced, computer-generated algorithm that considers over a dozen different momentum indicators to determine the most likely trend going forward. This “go/no go” algorithm is the single-best computer-generated indicator I look to for confirmation on when to enter a trade. When I layer it on top of my own indicators and analysis, it gives me a very high-level of confidence in my personal trading.. As you can see, I’ve highlighted several very quick and sizable recent gains… A 66% move in 4 days… a 40% move in a single day… a 22% move in 2 days… and a 42% move in 5 days… …And this is all just since June! In three of those reversals, you can see multiple, conflicting go/no-go markers along the trendline just before the chart legged up. These mixed signals are a classic indicator I’ve seen play out countless times before reversals. And that brings me to what I am seeing today. Those conflicting go/no-go markers suggest we could be very close to an inflection point, just like when I first alerted you to NLSP on August 22, before it made a 42% move higher. Looking at the chart of the last week, I’m not surprised those markers are flashing: As you can see, by the end of last week, NLSP was trading flat overall, but had tested new highs that were at least 10% moves up throughout the week. Yesterday morning kicked off with yet another 10% spike before settling in at recent support above $.70. This is often what the valley of a reversal will look like. Rarely will a stock rocket straight up at the end of a weeks-long drawdown. Instead, it will test the breakout repeatedly before making its ultimate swing. This is a great indication that an upside move could be coming, and that it could be dramatic. One of the most important items you should read on NLSP right now is the recent [shareholder letter]( their CEO recently issued. On top of the $10M private placement (which should firm up the company’s finances), one of the biggest news items I found that most traders overlooked is this line: “At this time we have received several non-binding term sheets for a potential partnership agreement within the pharmaceutical industry.” Take it how you will, but that sounds to me like NLSP could be very close to securing a game-changing partnership to help get their key product to market. That actually should not be surprising considering since in July of 2023, NLSP announced that the Phase 3 clinical trial (called the AMAZE Program) protocol to evaluate the safety and efficacy of Mazindol ER in patients with narcolepsy type 1 received approval from the independent Institutional Review Board ("IRB"). On top of that, On August 25, 2023, NLSP submitted a fast-track designation application for Mazindol ER for the treatment of narcolepsy to the FDA. That is HUGE. You see, standard reviews by the FDA for drug approval generally take about one year. A medicine that receives “Fast Track Designation” can be on the market within six months of the regulatory application. Fast-Track approval could literally change the fortunes of NLSP shareholders… overnight. It’s not only my technical analysis that gives NLSP a “thumbs up 👍” right now. As further confirmation, Yahoo! Finance is lighting up “bullish” on the slow stochastic oscillator, which you can read about in detail [here](. In brief, the slow stochastic helps us distinguish signal from noise by comparing the latest closing price to the highs and lows over the last 14 periods. This popular indicator is also giving a green light. Checking the news cycle, we just received [this report]( from Fintel last week: - The average one-year price target for NLS Pharmaceutics (NLSP) has been revised to $9.94 / share. This is an increase of 24.47% from the prior estimate of 7.99 dated August 31, 2023. - The price target is an average of many targets provided by analysts. The latest targets range from a low of 6.06 to a high of 14.18 / share. The average price target represents an increase of 1,286.84% from the latest reported closing price of 0.72 / share. If the analysts are right, the average price target represents a 10-bagger opportunity 💰 Of course, since NLSP is a clinical-stage pharmaceutical company, a lot of that depends on the success of the company’s drug trials… Between the explosive technical setup we are seeing along the the potentially game-changing developments recently, these things could all be catalysts for a serious rocket-ride for the stock 🚀. Will that happen for sure? The future is never certain in the markets. There is always risk. But as I said, based on my analysis, this is looking like a pitch right over the plate. You must do your own research, however. I’m mortal, after all, and I want all my readers to get used to studying charts, examining fundamentals, and ultimately making up their own minds. Nothing is ever guaranteed in life or trading, so make wise decisions that consider your own personal risk profile. I suggest first checking out the NLS Pharmaceutics website [here](, and especially browse through the [“Investors page](”. This is an opportunity that might be gone before you know it, so take the time to learn more about NLSP right now and see if it makes sense for you. From there, you’ll want to do an in-depth study of the stock’s chart. Again, the ticker is NLSP. Happy hunting! To Your Success, *This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results. Full Disclaimer  Questions or concerns about our products? Email Support@ragingbull.com © Copyright 2022, RagingBull  DISCLAIMER To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. Employees, owners, and other service providers of https:// ragingbull.com or RagingBull.com LLC are paid in whole or in part by commission based on their sales of Services to subscribers. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. Update your email preferences or unsubscribe [here]( © 2023 Bullseye Trades 62 Calef Hwy. #233 Lee, NH 03861, United States of America

EDM Keywords (218)

yesterday wrote world work whole well weeks way watching want waiting wait verified variety valley unsubscribe typical types trendline treatment trading trade tracked top timeframe time ticker thumbs throughout three think testimonials test terms taken take table swing surprised sure suit success stupid stocks stock speculative sounds solicitation signaling sidelines ship shared settling services seeing see securities securing screen scouring saw sales safety risks risk right rewarded revised reversals reversal result representations report relief registered received reason readers read rather rally quick question pull possibly plate plan patients part paid owners opportunity often obvious noise nlsp need necessary narcolepsy must mortal morning mind might medicine may markets market markers making made lows low lot look live line like lighting life licensed learn layer know keep july issuer interpret instituted indirectly indicators increase imperative huge history highs high happen gone going go gives get gave future found fortunes focus flashing firm fda factors explain exactly everyone event evaluate entitled enter enforce end employees email efficacy educational early driving drawn disbursements determine detail depends decides cusp could continue consult construed considers consider confirmation confidence concerns comparing company communication coming comes cluster close charts chart catalysts carries business bullish buck brought brings brief breaking bonds bid believed become banging average attention analysts analysis amount america affiliates advertisers addition actually action 70 1000

Marketing emails from bullseyeoptiontrading.com

View More
Sent On

07/12/2024

Sent On

07/12/2024

Sent On

06/12/2024

Sent On

05/12/2024

Sent On

04/12/2024

Sent On

03/12/2024

Email Content Statistics

Subscribe Now

Subject Line Length

Data shows that subject lines with 6 to 10 words generated 21 percent higher open rate.

Subscribe Now

Average in this category

Subscribe Now

Number of Words

The more words in the content, the more time the user will need to spend reading. Get straight to the point with catchy short phrases and interesting photos and graphics.

Subscribe Now

Average in this category

Subscribe Now

Number of Images

More images or large images might cause the email to load slower. Aim for a balance of words and images.

Subscribe Now

Average in this category

Subscribe Now

Time to Read

Longer reading time requires more attention and patience from users. Aim for short phrases and catchy keywords.

Subscribe Now

Average in this category

Subscribe Now

Predicted open rate

Subscribe Now

Spam Score

Spam score is determined by a large number of checks performed on the content of the email. For the best delivery results, it is advised to lower your spam score as much as possible.

Subscribe Now

Flesch reading score

Flesch reading score measures how complex a text is. The lower the score, the more difficult the text is to read. The Flesch readability score uses the average length of your sentences (measured by the number of words) and the average number of syllables per word in an equation to calculate the reading ease. Text with a very high Flesch reading ease score (about 100) is straightforward and easy to read, with short sentences and no words of more than two syllables. Usually, a reading ease score of 60-70 is considered acceptable/normal for web copy.

Subscribe Now

Technologies

What powers this email? Every email we receive is parsed to determine the sending ESP and any additional email technologies used.

Subscribe Now

Email Size (not include images)

Font Used

No. Font Name
Subscribe Now

Copyright © 2019–2025 SimilarMail.